Floatz logo

NEPENTHE

Stem Cell Leukemia

Children's Cancer Hospital Egypt 57357Small moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

80 Active assets in the Stem Cell Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Children's Oncology Group
Phase 3BB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
University of Washington
Phase 3BB
MERCAPTOPURINE ANHYDROUS
SWOG Cancer Research Network
Phase 3BB
PEGASPARGASE
Children's Oncology Group
Phase 3BB
Daunorubicin
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

NEPENTHE is also rated in:

PainDormant
BBB
Indicative ·
77 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
75 / 100
View asset →
chronic pain syndromeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →